List of Excipients in Branded Drug BELSOMRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	BELSOMRA	suvorexant	0006-0005	CELLULOSE, MICROCRYSTALLINE	2033-05-29
Merck Sharp & Dohme LLC	BELSOMRA	suvorexant	0006-0005	COPOVIDONE K25-31	2033-05-29
Merck Sharp & Dohme LLC	BELSOMRA	suvorexant	0006-0005	CROSCARMELLOSE SODIUM	2033-05-29
Merck Sharp & Dohme LLC	BELSOMRA	suvorexant	0006-0005	FERRIC OXIDE YELLOW	2033-05-29
Merck Sharp & Dohme LLC	BELSOMRA	suvorexant	0006-0005	FERROSOFERRIC OXIDE	2033-05-29
Merck Sharp & Dohme LLC	BELSOMRA	suvorexant	0006-0005	HYPROMELLOSE	2033-05-29

Belsomra Excipient Strategy and Commercial Opportunities for Suvorexant

Last updated: September 8, 2026

Belsomra is the branded form of suvorexant, a small-molecule dual orexin receptor antagonist approved by the FDA for insomnia characterized by difficulties with sleep onset and sleep maintenance. Its formulation is relatively simple: immediate-release film-coated tablets in 5 mg, 10 mg, 15 mg, and 20 mg strengths. The main formulation opportunities are generic development, excipient substitution, improved dissolution, lower-dose products, and differentiated delivery systems rather than biologic-style biosimilar programs.

The commercial case is strongest for suppliers and manufacturers that can solve suvorexant’s low-dose content-uniformity, solubility, dissolution, powder-flow, and controlled-substance manufacturing requirements. A conventional generic tablet is the most direct route. Reformulated products may create longer-term value but face stronger clinical, regulatory, patent, and commercial barriers.

What is Belsomra and how is it formulated?

Belsomra contains suvorexant, an orexin OX1 and OX2 receptor antagonist. The FDA-approved product is an immediate-release oral tablet taken once nightly, within 30 minutes of going to bed and with at least seven hours remaining before planned awakening.

Product attribute	Belsomra information
Active ingredient	Suvorexant
Drug class	Dual orexin receptor antagonist
FDA indication	Insomnia characterized by difficulties with sleep onset and sleep maintenance
Dosage forms	Immediate-release film-coated tablets
Strengths	5 mg, 10 mg, 15 mg, 20 mg
Route	Oral
Controlled substance	Schedule IV in the United States
Original FDA approval	2014
Innovator	Merck & Co.
Key formulation issue	Low drug loading and challenging aqueous solubility
Biosimilar pathway	Not applicable; suvorexant is a small molecule

The FDA label identifies inactive ingredients including lactose monohydrate, croscarmellose sodium, povidone, colloidal silicon dioxide, and magnesium stearate. The film coating contains hypromellose, titanium dioxide, and triacetin, according to the prescribing information and product labeling.[1]

The formulation has a conventional excipient architecture:

1. Lactose monohydrate as a diluent.
2. Croscarmellose sodium as a superdisintegrant.
3. Povidone as a binder.
4. Colloidal silicon dioxide as a glidant.
5. Magnesium stearate as a lubricant.
6. Hypromellose-based film coating with titanium dioxide and triacetin.

This composition gives generic developers several substitution opportunities, but every change must preserve dissolution, assay, content uniformity, stability, and bioequivalence.

What excipient strategy is most suitable for generic suvorexant tablets?

The lowest-risk strategy is a Q1/Q2 or Q1/Q3-equivalent immediate-release tablet using excipients with established oral safety and extensive regulatory precedent. A generic developer should first reproduce the reference product’s critical performance characteristics before pursuing a differentiated formulation.

Direct-excipient matching

The simplest development path uses the same functional excipient classes as Belsomra:

Formulation function	Reference-product class	Potential generic alternatives
Diluent	Lactose monohydrate	Mannitol, microcrystalline cellulose, dibasic calcium phosphate, spray-dried lactose
Binder	Povidone	Copovidone, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose
Disintegrant	Croscarmellose sodium	Crospovidone, sodium starch glycolate
Glidant	Colloidal silicon dioxide	Alternative silicon dioxide grades, selected starch-based flow aids
Lubricant	Magnesium stearate	Sodium stearyl fumarate, alternative magnesium stearate grades
Film former	Hypromellose	Polyvinyl alcohol, hypromellose-based premixes
Plasticizer	Triacetin	Polyethylene glycol, other approved coating plasticizers
Opacifier	Titanium dioxide	Iron oxides or titanium-dioxide-containing systems, subject to jurisdictional requirements

The main development risk is not excipient novelty. It is the effect of excipient grade, particle size, surface area, moisture content, compression force, and lubricant exposure on dissolution and bioavailability.

Low-dose content uniformity

The 5 mg and 10 mg tablets create a more demanding blend-uniformity problem than the 15 mg and 20 mg strengths. Suvorexant may represent a small fraction of total tablet mass, making segregation and sampling error important process risks.

Preferred controls include:

• Narrow active-ingredient particle-size distribution.
• Geometric dilution or ordered blending.
• Carrier excipients with compatible density and morphology.
• Low-shear blending followed by validated hold-time studies.
• In-process blend uniformity and tablet-weight controls.
• Separate evaluation of direct compression and wet granulation.

A higher-density filler may improve flow but increase segregation if its density differs materially from suvorexant. Microcrystalline cellulose can improve compactibility, while spray-dried lactose can support direct compression and more uniform blending. The optimal choice depends on the active’s particle size, electrostatic behavior, and bulk density.

Dissolution and solubility management

Suvorexant is a hydrophobic compound with limited aqueous solubility. A generic product therefore should not treat disintegration as a complete surrogate for dissolution. A tablet can disintegrate rapidly while generating slow or variable drug release.

Potential approaches include:

• Micronized active pharmaceutical ingredient.
• Wetting-agent screening.
• Amorphous solid dispersion.
• Co-milling with a hydrophilic carrier.
• Spray drying.
• Solid-state control through polymorph or crystallinity management.
• Surfactant-containing granulation.
• Particle-size engineering.

A conventional micronized formulation is commercially attractive because it can remain within an immediate-release generic framework. An amorphous solid dispersion may improve dissolution but increases manufacturing complexity, physical-stability risk, and analytical burden.

What formulation patents may protect suvorexant products?

Suvorexant’s patent estate is expected to include several claim categories:

Claim category	Commercial relevance
Composition of matter	Protects suvorexant molecule and core chemical structure
Salt, polymorph, or crystalline form	May restrict alternative solid forms
Pharmaceutical composition	May cover dosage forms and excipient combinations
Method of treatment	May cover treatment of insomnia or sleep-related disorders
Dose and administration method	May cover timing, strength, or patient-use parameters
Manufacturing process	May cover preparation of intermediates or active ingredient
Formulation or release profile	May create secondary barriers to alternative dosage forms

The controlling source for U.S. patent listings is the FDA Orange Book. The reference drug’s exclusivity and listed-patent status must be assessed against the current Orange Book entry, patent-term adjustments, pediatric extensions, terminal disclaimers, and any litigation or settlement affecting launch timing.[2]

For a conventional generic, the key legal questions are:

• Whether the relevant composition-of-matter patent has expired.
• Whether any formulation patents remain listed.
• Whether method-of-use patents can be carved out through a Section viii statement.
• Whether an ANDA sponsor must submit a Paragraph IV certification.
• Whether the patent holder files suit within the statutory 45-day period.
• Whether an agreement imposes a delayed-launch date.

Method-of-use patents may be less disruptive to a carved-out generic than composition or formulation patents. A drug-specific formulation claim is more difficult to avoid if it covers the tablet’s release characteristics or a mandatory excipient combination.

When does Belsomra lose exclusivity?

Belsomra’s regulatory exclusivity began with its 2014 FDA approval, but regulatory exclusivity and patent exclusivity are separate. FDA approval exclusivity does not establish the final date on which a generic can launch.

Exclusivity issue	Relevance to suvorexant
New chemical entity exclusivity	Applied after original FDA approval and generally lasts five years
ANDA filing timing	Paragraph IV filings may begin after the statutory restriction period
Patent expiration	Depends on the individual patent, PTA, PTE, and terminal-disclaimer record
Pediatric extension	Can add six months when granted
Method-of-use patents	May be addressed through label carve-outs
180-day generic exclusivity	May apply to the first qualifying Paragraph IV filer
Controlled-substance requirements	Apply independently of patent expiry

The commercial launch date is therefore determined by the latest enforceable barrier, not simply by the end of FDA exclusivity. A generic sponsor can also face launch risk from litigation, regulatory deficiencies, manufacturing readiness, and controlled-substance quota or registration requirements.

What is the Orange Book status of Belsomra?

Belsomra is an FDA-approved small-molecule product listed in the Orange Book under suvorexant. The Orange Book identifies the reference listed drug, dosage forms, strengths, therapeutic equivalence information, and any listed patents or exclusivity codes.[2]

A complete freedom-to-launch review should classify each listed patent by:

1. Expiration date.
2. Patent type.
3. Claim scope.
4. Applicability to each strength.
5. Ability to use a label carve-out.
6. Litigation history.
7. Settlement restrictions.
8. Whether the patent is still listed or has been delisted.

The most important distinction is between patents covering suvorexant itself and patents covering a particular formulation or use. An ANDA sponsor with a non-infringing formulation may have a stronger position against formulation claims, but a composition-of-matter patent can block all ordinary suvorexant products until expiration or settlement.

How strong is the patent estate for Belsomra?

The estate is strongest when it relies on composition-of-matter protection or a broad, enforceable solid-state claim. It is weaker when protection depends on narrow excipient combinations that can be avoided through formulation design.

Patent feature	Relative barrier to generic entry
Broad composition-of-matter claim	High
Valid crystalline-form claim	High to moderate
Narrow excipient combination	Moderate to low
Method-of-use claim with label carve-out	Low to moderate
Process claim with readily available alternatives	Low
Unlisted formulation concept	Limited Orange Book impact for ANDA timing

For excipient companies, this distinction creates a commercial opening. A supplier that can provide a functionally equivalent excipient system without reproducing a protected combination may support a non-infringing generic formulation. The strongest value proposition is a validated platform that improves dissolution or content uniformity while reducing dependence on the reference product’s exact inactive-ingredient profile.

What commercial opportunities exist in Belsomra excipients?

Generic finished-dose supply

The largest near-term opportunity is supply to ANDA manufacturers. A supplier can offer:

• Direct-compression blends.
• Co-processed diluent-disintegrant systems.
• Low-moisture excipient grades.
• Lubricant systems designed for rapid dissolution.
• Film-coating premixes.
• Excipient systems optimized for low-dose tablets.

The customer value is lower development time, better process capability, and reduced batch failure risk.

Excipient platform licensing

A proprietary formulation platform could be licensed to generic manufacturers if it provides a measurable advantage in:

• Blend uniformity.
• Dissolution at physiologically relevant pH.
• Tablet robustness.
• Reduced compression force.
• Improved stability.
• Lower manufacturing cost.
• Reduced solvent use.

The licensing model could combine an upfront technology fee, development milestones, and per-unit royalties. A formulation patent must be evaluated carefully before commercialization because a technology that improves performance but overlaps an Orange Book-listed claim may not provide a practical launch pathway.

505(b)(2) reformulation

A 505(b)(2) product could target:

• Lower-dose administration.
• Liquid oral delivery.
• Orally disintegrating tablets.
• Sprinkle capsules.
• Modified-release dosing.
• Improved administration for older adults.
• Reduced next-day impairment through altered exposure.
• Improved dissolution in patients with variable gastric conditions.

These products face more demanding clinical and regulatory requirements than an ANDA. A reformulation must establish the relevance of the new dosage form, demonstrate adequate exposure, and address safety concerns related to sedation, CNS depression, next-day psychomotor impairment, and complex sleep behaviors.[1,3]

Pediatric and geriatric delivery systems

A liquid or orally disintegrating formulation could create value where swallowing tablets is difficult. The principal development issues are taste masking, dose measurement, physical stability, preservative selection, and exposure control.

Taste-masking technologies may include:

• Ion-exchange resins.
• Polymer coating.
• Lipid barriers.
• Cyclodextrin complexation.
• Multiparticulate systems.
• Flavor and sweetener systems.

Suvorexant’s CNS activity makes dose accuracy important. A pediatric-oriented product would also require a clear clinical rationale because insomnia treatment in children is not automatically addressed by an adult formulation.

Contract development and manufacturing

CDMOs with capabilities in controlled-substance handling, low-dose blending, high-potency containment, and solid-state characterization can compete for suvorexant development programs. Services with the greatest commercial value include:

• API particle engineering.
• Amorphous dispersion development.
• Continuous blending.
• Tablet compression.
• Film coating.
• Dissolution method development.
• Stability studies.
• ANDA CMC support.
• Schedule IV manufacturing controls.

Which companies are challenging Belsomra?

Suvorexant is a small molecule, so the relevant competitive group consists of generic-drug companies and potential 505(b)(2) developers rather than biosimilar manufacturers. Publicly verifiable challenge status depends on the current FDA Orange Book, ANDA filing records, court dockets, and company disclosures.

The likely competitive categories are:

Competitor type	Product strategy
Large generic manufacturer	Conventional immediate-release tablets
Regional generic company	Selected strengths or licensed product
Specialty CNS company	Reformulated or differentiated dosage form
Excipient supplier	Enabling formulation platform
CDMO	Development and commercial manufacturing
API manufacturer	Micronized or engineered suvorexant supply

FDA approval of a generic does not necessarily mean immediate commercial launch. Patent settlements, controlled-substance registration, manufacturing scale-up, and supply agreements can delay market entry.

How does Belsomra compare with competing insomnia drugs?

Product	Active ingredient	Drug class	Formulation opportunity
Belsomra	Suvorexant	Dual orexin antagonist	Generic tablet, ODT, liquid, solid-state optimization
Dayvigo	Lemborexant	Dual orexin antagonist	Similar CNS and formulation considerations
Quviviq	Daridorexant	Dual orexin antagonist	Newer patent estate and differentiated exposure profile
Ambien	Zolpidem	Nonbenzodiazepine hypnotic	Mature generic market
Lunesta	Eszopiclone	Cyclopyrrolone hypnotic	Mature generic market
Rozerem	Ramelteon	Melatonin receptor agonist	Generic and formulation competition

Belsomra competes within the orexin-antagonist class as well as against established generic hypnotics. A new excipient strategy must therefore improve manufacturing economics or patient usability enough to offset the cost of entering a product with established therapeutic substitutes.

What generic launch risks exist for suvorexant?

The principal launch risks are:

• Unexpired composition or formulation patents.
• Paragraph IV litigation.
• Settlement-based launch restrictions.
• Failure to demonstrate bioequivalence across strengths.
• Dissolution differences caused by excipient substitution.
• Low-dose content-uniformity failures.
• Controlled-substance manufacturing and distribution requirements.
• API supply concentration.
• Brand defense through authorized generic or contracting.
• Weak price economics after multiple generic entrants.

Revenue exposure is difficult to quantify from public disclosures because Merck has not consistently reported Belsomra as a separately identifiable revenue line. A commercial forecast should therefore model total insomnia-market erosion rather than rely on a standalone Belsomra revenue figure.

Key Takeaways

• Belsomra is a small-molecule suvorexant tablet, so biosimilar risk is irrelevant.
• The practical generic opportunity is an immediate-release tablet using familiar excipient classes.
• The most important technical risks are low-dose uniformity, dissolution, hydrophobicity, and solid-state control.
• Excipient substitution can create value if it improves process capability without reproducing protected formulation claims.
• A 505(b)(2) opportunity exists for orally disintegrating, liquid, sprinkle, and other differentiated dosage forms, but clinical and regulatory requirements are higher.
• The FDA Orange Book, patent records, litigation dockets, and settlement terms determine the actual launch window.
• Excipient suppliers and CDMOs can compete even when the finished-dose market becomes price-sensitive.
• Conventional generic entry is commercially more credible than a major reformulation unless the new product solves a clear administration or exposure problem.

FAQs

Is Belsomra an extended-release formulation?

No. Belsomra is marketed as an immediate-release film-coated tablet. The main formulation objective is rapid and consistent release rather than prolonged delivery.

Can a generic Belsomra use different excipients?

Yes. A generic applicant can use different inactive ingredients if the formulation meets applicable FDA requirements for safety, quality, bioequivalence, dissolution, stability, and labeling.

Is suvorexant suitable for an orally disintegrating tablet?

Potentially. An orally disintegrating tablet could improve administration for patients who have difficulty swallowing, but taste masking, dose uniformity, mechanical strength, and exposure must be demonstrated.

Does Belsomra require special manufacturing controls?

Yes. Suvorexant is a Schedule IV controlled substance in the United States. Manufacturers and distributors must comply with applicable controlled-substance registration, security, recordkeeping, quota, and distribution requirements.

What is the most attractive excipient opportunity around Belsomra?

The strongest opportunity is a validated low-dose immediate-release platform that improves blend uniformity and dissolution while supporting direct compression or efficient granulation. A platform with regulatory precedent across multiple strengths is more commercially useful than a novel excipient with a narrow application.

References

1. U.S. Food and Drug Administration. (2024). Belsomra (suvorexant) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2017). Belsomra: Clinical review and approval documentation. Center for Drug Evaluation and Research.